SMN2 and proximal spinal muscular atrophy: Onasemnogene abeparvovec targets all presymptomatic SMA patients carrying a genetic SMA diagnosis with two and three SMN2 copies, with ongoing global deliberations concerning cases with four SMN2 copies.